| First Author | Zhang N | Year | 2020 |
| Journal | Eur J Immunol | Volume | 50 |
| Issue | 11 | Pages | 1820-1833 |
| PubMed ID | 32460355 | Mgi Jnum | J:298129 |
| Mgi Id | MGI:6473055 | Doi | 10.1002/eji.202048543 |
| Citation | Zhang N, et al. (2020) Loss of core fucosylation enhances the anticancer activity of cytotoxic T lymphocytes by increasing PD-1 degradation. Eur J Immunol 50(11):1820-1833 |
| abstractText | As an immune checkpoint, programmed cell death 1 (PD-1) and its ligand (PD-L1) pathway plays a crucial role in CD8(+) cytotoxic T lymphocytes (CTL) activation and provides antitumor responses. The N-glycans of PD-1 and PD-L1 are highly core fucosylated, which are solely catalyzed by the core fucosyltransferase (Fut8). However, the precise biological mechanisms underlying effects of core fucosylation of PD-1 and PD-L1 on CTL activation have not been fully understood. In this study, we found that core fucosylation was significantly upregulated in lung adenocarcinoma. Compared to those of Fut8(+/+) OT-I mice, the lung adenocarcinoma formation induced by urethane was markedly reduced in Fut8(-/-) OT-I mice. De-core fucosylation of PD-1 compromised its expression on Fut8(-/-) CTL, resulted in enhanced Fut8(-/-) CTL activation and cytotoxicity, leading to more efficient tumor eradication. Indeed, loss of core fucosylation significantly enhanced the PD-1 ubiquitination and in turn led to the degradation of PD-1 in the proteasome. Our current work indicates that inhibition of core fucosylation is a unique strategy to reduce PD-1 expression for the antilung adenocarcinoma immune therapy in the future. |
